|
1
|
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu
ZY, Shi W, Jiang J, Yao PP and Zhu HP: Risk factors and preventions
of breast cancer. Int J Biol Sci. 13:1387–1397. 2017. View Article : Google Scholar
|
|
2
|
Rahman M and Mohammed S: Breast cancer
metastasis and the lymphatic system. Oncol Lett. 10:1233–1239.
2015. View Article : Google Scholar
|
|
3
|
Niell BL, Freer PE, Weinfurtner RJ, Arleo
EK and Drukteinis JS: Screening for breast cancer. Radiol Clin
North Am. 55:1145–1162. 2017. View Article : Google Scholar
|
|
4
|
Nothacker M, Duda V, Hahn M, Warm M,
Degenhardt F, Madjar H, Weinbrenner S and Albert US: Early
detection of breast cancer: Benefits and risks of supplemental
breast ultrasound in asymptomatic women with mammographically dense
breast tissue. A systematic review. BMC Cancer. 9:3352009.
View Article : Google Scholar
|
|
5
|
Drukteinis JS, Mooney BP, Flowers CI and
Gatenby RA: Beyond mammography: New frontiers in breast cancer
screening. Am J Med. 126:472–479. 2013. View Article : Google Scholar
|
|
6
|
Baskın Y and Yiğitbaşı T: Clinical
proteomics of breast cancer. Curr Genomics. 11:528–536. 2010.
View Article : Google Scholar
|
|
7
|
Liu C: The application of SELDI-TOF-MS in
clinical diagnosis of cancers. J Biomed Biotechnol.
2011:2458212011. View Article : Google Scholar
|
|
8
|
Li J, Orlandi R, White CN, Rosenzweig J,
Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, et al:
Independent validation of candidate breast cancer serum biomarkers
identified by mass spectrometry. Clin Chem. 51:2229–2235. 2005.
View Article : Google Scholar
|
|
9
|
Atahan K, Küpeli H, Gür S, Yiğitbaşı T,
Baskın Y, Yiğit S, Deniz M, Cökmez A and Tarcan E: The value of
serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast
cancer. Int J Med Sci. 8:148–155. 2011. View Article : Google Scholar
|
|
10
|
Belluco C, Petricoin EF, Mammano E,
Facchiano F, Ross-Rucker S, Nitti D, Di Maggio C, Liu C, Lise M,
Liotta LA, et al: Serum proteomic analysis identifies a highly
sensitive and specific discriminatory pattern in stage 1 breast
cancer. Ann Surg Oncol. 14:2470–2476. 2007. View Article : Google Scholar
|
|
11
|
van Winden AW, Gast MC, Beijnen JH,
Rutgers EJT, Grobbee DE, Peeters PH and van Gils CH: Validation of
previously identified serum biomarkers for breast cancer with
SELDI-TOF MS: A case control study. BMC Med Genomics. 2:42009.
View Article : Google Scholar
|
|
12
|
Chung L, Moore K, Phillips L, Boyle FM,
Marsh DJ and Baxter RC: Novel serum protein biomarker panel
revealed by mass spectrometry and its prognostic value in breast
cancer. Breast Cancer Res. 16:R632014. View
Article : Google Scholar
|
|
13
|
Singletary SE and Connolly JL: Breast
cancer staging: working with the sixth edition of the AJCC Cancer
Staging Manual. CA Cancer J Clin. 56:37–47. 2006. View Article : Google Scholar
|
|
14
|
Harris L, Fritsche H, Mennel R, Norton L,
Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American
Society of Clinical Oncology, : American Society of Clinical
Oncology 2007 update of recommendations for the use of tumor
markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007.
View Article : Google Scholar
|
|
15
|
Paweletz CP, Gillespie JW, Ornstein DK,
Simone NL, Brown MR, Cole KA, Wang QH, Huang J, Hu N, Yip TT, et
al: Rapid protein display profiling of cancer progression directly
from human tissue using a protein biochip. Drug Dev Res. 49:34–42.
2000. View Article : Google Scholar
|
|
16
|
Nakanishi T, Shimizu A, Okamoto N,
Ingendoh A and Kanai M: Analysis of serum protein precipitated with
antiserum by matrix-assisted laser desorption
ionization/time-of-flight and electrospray ionization mass
spectrometry as a clinical laboratory test. J Am Soc Mass Spectrom.
6:854–859. 1995. View Article : Google Scholar
|
|
17
|
Lacey JM, Bergen HR, Magera MJ, Naylor S
and O'Brien JF: Rapid determination of transferrin isoforms by
immunoaffinity liquid chromatography and electrospray mass
spectrometry. Clin Chem. 47:513–518. 2001.
|
|
18
|
Vlahou A, Laronga C, Wilson L, Gregory B,
Fournier K, McGaughey D, Perry RR, Wright GL Jr and Semmes OJ: A
novel approach toward development of a rapid blood test for breast
cancer. Clin Breast Cancer. 4:203–209. 2003. View Article : Google Scholar
|
|
19
|
Yao F, Zhang C, Du W, Liu C and Xu Y:
Identification of gene-expression signatures and protein markers
for breast cancer grading and staging. PLoS One. 10:e01382132015.
View Article : Google Scholar
|
|
20
|
Diamandis EP: Point: Proteomic patterns in
biological fluids: Do they represent the future of cancer
diagnostics? Clin Chem. 49:1272–1275. 2003. View Article : Google Scholar
|
|
21
|
Higgins SA, Matloff ET, Rimm DL, Dziura J,
Haffty BG and King BL: Patterns of reduced nipple aspirate fluid
production and ductal lavage cellularity in women at high risk for
breast cancer. Breast Cancer Res. 7:R1017–R1022. 2005. View Article : Google Scholar
|
|
22
|
Li J, Zhang Z, Rosenzweig J, Wang YY and
Chan DW: Proteomics and bioinformatics approaches for
identification of serum biomarkers to detect breast cancer. Clin
Chem. 48:1296–1304. 2002.
|
|
23
|
Ford D, Easton DF, Stratton M, Narod S,
Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J,
et al The Breast Cancer Linkage Consortium, : Genetic heterogeneity
and penetrance analysis of the BRCA1 and BRCA2 genes in breast
cancer families. Am J Hum Genet. 62:676–689. 1998. View Article : Google Scholar
|
|
24
|
Vos S, Moelans CB and van Diest PJ: BRCA
promoter methylation in sporadic versus BRCA germline
mutation-related breast cancers. Breast Cancer Res. 19:642017.
View Article : Google Scholar
|
|
25
|
Neagu M, Constantin C, Tanase C and Boda
D: Patented biomarker panels in early detection of cancer. Recent
Pat Biomark. 1:10–24. 2011. View Article : Google Scholar
|
|
26
|
Mathelin C, Cromer A, Wendling C,
Tomasetto C and Rio MC: Serum biomarkers for detection of breast
cancers: A prospective study. Breast Cancer Res Treat. 96:83–90.
2006. View Article : Google Scholar
|
|
27
|
Atalay C and Kubilay D: The results of
screening with SELDI-TOF-MS method in breast cancer diagnosis. J
Breast Health. 7:106–108. 2011.
|
|
28
|
Stearns V, Yamauchi H and Hayes DF:
Circulating tumor markers in breast cancer: Accepted utilities and
novel prospects. Breast Cancer Res Treat. 52:239–259. 1998.
View Article : Google Scholar
|
|
29
|
Gautam A and Verma S, Pantola C and Verma
S: Utility of CA 15-3 as diagnostic and prognostic marker in breast
cancer. IOSR-JDMS. 14:17–20. 2015.
|
|
30
|
Geng B, Liang MM, Ye XB and Zhao WY:
Association of CA 15-3 and CEA with clinicopathological parameters
in patients with metastatic breast cancer. Mol Clin Oncol.
3:232–236. 2015. View Article : Google Scholar
|
|
31
|
Zeidan BA, Cutress RI, Hastie C, Mirnezami
AH, Packham G and Townsend PA: SELDI-TOF-MS proteomics in breast
cancer. Clin Proteomics. 5:133–147. 2009. View Article : Google Scholar
|
|
32
|
Yin P, Lehmann R and Xu G: Effects of
pre-analytical processes on blood samples used in metabolomics
studies. Anal Bioanal Chem. 407:4879–4892. 2015. View Article : Google Scholar
|
|
33
|
Chandramouli K and Qian PY: Proteomics:
Challenges, techniques and possibilities to overcome biological
sample complexity. Hum Genomics Proteomics. 2009:2392042009.
View Article : Google Scholar
|
|
34
|
Muthu M, Vimala A, Mendoza OH and Gopal J:
Tracing the voyage of SELDI-TOF-MS in cancer biomarker discovery
and its current depreciation trend-need for resurrection? Trends
Analyt Chem. 76:95–101. 2016. View Article : Google Scholar
|
